儿茶上清丸 | China Drugs ListErcha Shangqing pills | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- 湖北齐进药业有限公司Hubei Qijin Pharmaceutical Co., Ltd.
- 药品类型
- 中成药Traditional Chinese medicine
- 治疗领域
- 麻醉与疼痛Anesthesia & pain
- 公开来源记录的适应症
- 清热退火,解毒敛疮,止痛。用于轻型复发性阿弗他溃疡上焦实热证。症见:口舌生疮,溃疡疼痛,口渴欲饮,口粘口臭,舌质红,舌苔黄或黄腻,脉弦洪或弦数。TCM actions: clears heat and fire, resolves toxicity, promotes healing of ulcers and relieves pain. For minor recurrent aphthous ulcers with the TCM pattern of excess heat in the upper burner. Symptoms include mouth or tongue ulcers, painful ulcers, thirst, a sticky sensation in the mouth, bad breath, a red tongue with a yellow or yellow-greasy coating, and a wiry-surging or wiry-rapid pulse.
- 适应症来源与口径
- 来源日期： 2024, 2026. 适应症转录自国家医保局公开的企业申报资料；不代表已核实完整的现行说明书。Source date(s): 2024, 2026. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.
- 说明书信息局限
- 适应症已与官方公开申报资料核对。尚未取得完整原始说明书。Indications checked against an official public submission. The full original prescribing information is still unavailable.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 已纳入国家医保（乙类）Included in national insurance (Category B)
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 清热退火,解毒敛疮,止痛。用于轻型复发性阿弗他溃疡上焦实热证。症见:口舌生疮,溃疡疼痛,口渴欲饮,口粘口臭,舌质红,舌苔黄或黄腻,脉弦洪或弦数。TCM actions: clears heat and fire, resolves toxicity, promotes healing of ulcers and relieves pain. For minor recurrent aphthous ulcers with the TCM pattern of excess heat in the upper burner. Symptoms include mouth or tongue ulcers, painful ulcers, thirst, a sticky sensation in the mouth, bad breath, a red tongue with a yellow or yellow-greasy coating, and a wiry-surging or wiry-rapid pulse.
- 医保期限
- 2025-01-01 至 2026-12-312025-01-01 to 2026-12-31
- 医保核查说明
- 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.